← Back to Search

Mobile Health Application and Wearable Device

Mobile Health Technology for Colorectal Cancer Recovery

N/A
Waitlist Available
Led By Heather Yeo, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject is scheduled to undergo surgery for a GI cancer (pancreatic, hepatic, gastric, small bowel, colon, or rectal cancers)
Subject speaks English
Must not have
Subject has sepsis from another source
Subject is undergoing emergent surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Summary

This trial will test if mobile devices can help prevent readmission in patients who have had major GI cancer surgery.

Who is the study for?
This trial is for English-speaking adults over 18 who own a smartphone and are scheduled for GI cancer surgery (pancreatic, liver, stomach, small bowel, colon or rectal). It's not suitable for those with dementia, substance abuse issues, sepsis from another source or needing emergency surgery.
What is being tested?
The study compares the effectiveness of using mobile health apps and Fitbit alongside standard care versus standard care alone in preventing hospital readmission after major GI cancer surgeries.
What are the potential side effects?
Since this trial involves non-invasive tools like mobile apps and Fitbit devices along with usual medical care, side effects may be minimal but could include discomfort or skin irritation from wearing the device.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am scheduled for surgery for a GI cancer.
Select...
I speak English.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently suffering from sepsis caused by another condition.
Select...
I am scheduled for urgent surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Readmission rate
Secondary study objectives
Healthcare utilization rates
Patient Satisfaction with Device
Quality of life: Return to Baseline Function-Activities of Daily Living (ADLs)
+1 more

Side effects data

From 2007 Phase 4 trial • 552 Patients • NCT00110890
7%
Diarrhoea
7%
Vomiting
3%
Nausea
3%
Nasopharyngitis
3%
Muscle spasms
1%
Angina pectoris
1%
Myocardial infarction
1%
Pericarditis
1%
Chest discomfort
1%
Hernia
1%
Jaundice
1%
Gastroenteritis
1%
Arteriovenous fistula thrombosis
1%
Joint dislocation
1%
Joint injury
1%
Shunt occlusion
1%
Shunt thrombosis
1%
Blood potassium increased
1%
Fluid retention
1%
Hypovolaemia
1%
Pancreatic carcinoma
1%
Cognitive disorder
1%
Skin ulcer
1%
Catheter placement
1%
Hypertensive crisis
1%
Arteriovenous fistula occlusion
1%
Orthostatic hypotension
1%
Cardiac arrest
1%
Chest pain
1%
Pyrexia
1%
Cholecystitis
1%
Arthritis bacterial
1%
Bacterial sepsis
1%
Fall
1%
Back pain
1%
Pain in extremity
1%
Dyspnoea
1%
Nephrectomy
1%
Hypotension
1%
Peripheral ischaemia
1%
Atrial flutter
1%
Cardiac asthma
1%
Abdominal pain
1%
Sudden cardiac death
1%
Transplant rejection
1%
Perianal abscess
1%
Pneumonia
1%
Urinary tract infection
1%
Ankle fracture
1%
Arteriovenous fistula site complication
1%
Rib fracture
1%
Cerebral infarction
1%
Gastrointestinal haemorrhage
1%
Catheter related infection
1%
Atrial fibrillation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Standard Care
Cinacalcet

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Standard of careExperimental Treatment1 Intervention
Participants will receive standard of care
Group II: Mobile app and Fitbit + Standard of careActive Control1 Intervention
Mobile health application and Fitbit + standard of care: Participants will utilize mobile app and Fitbit and standard of care. Mobility data will be generated using a mobile health tracker designed for smartphone devices.

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
1,077 Previous Clinical Trials
1,320,560 Total Patients Enrolled
Damon Runyon Cancer Research FoundationOTHER
9 Previous Clinical Trials
1,038 Total Patients Enrolled
Heather Yeo, MDPrincipal InvestigatorWeill Medical College of Cornell University

Media Library

Mobile health application and Fitbit (Mobile Health Application and Wearable Device) Clinical Trial Eligibility Overview. Trial Name: NCT03623464 — N/A
Pancreatic Cancer Research Study Groups: Mobile app and Fitbit + Standard of care, Standard of care
Pancreatic Cancer Clinical Trial 2023: Mobile health application and Fitbit Highlights & Side Effects. Trial Name: NCT03623464 — N/A
Mobile health application and Fitbit (Mobile Health Application and Wearable Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03623464 — N/A
~5 spots leftby Feb 2025